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Abstract This review outlines the effects of 1,2,3,4-tetra-
hydroisoquinoline (TIQ) and its derivative, 1-methyl-
1,2,3,4-tetrahydroisoquinoline (1MeTIQ), endogenous sub-
stances imbued with high pharmacological potential and
broad spectrum of action in brain. 1MeTIQ has gained spe-
cial interest as a neuroprotectant, and its ability to antagonize
the behavioral syndrome produced by well-known neuro-
toxins (e.g., MPTP; rotenone). This review is thus focused on
mechanisms of action of 1MeTIQ in behavioral, neuro-
chemical, and molecular studies in rodents; also, effects of
TIQ and 1MeTIQ on dopamine metabolism; and neuropro-
tective properties of TIQ and 1MeTIQ in vitro and in vivo.
Finally, antiaddictive properties of 1MeTIQ will be descri-
bed in cocaine self-administered rats. Findings implicate
TIQ and especially its methyl derivative 1MeTIQ in unique
and complex mechanisms of neuroprotection in various
neurodegenerative illnesses of the central nervous system.
We believe that MAO inhibition, free radicals scavenging
properties, and antagonism to the glutamatergic system may
play an essential role in neuroprotection. In addition, the
results strongly support the view that 1MeTIQ has a con-
siderable potential as a drug for combating substance abuse,
through the attenuation of craving.
Keywords TIQ  1MeTIQ  Brain dopamine metabolism 
Neuroprotection  Addiction  Rat
Introduction
1,2,3,4-Tetrahydroisoquinoline (TIQ) is a member of a
family of tetrahydroisoquinolines widespread in plant and
animal and human brains (McNaught et al. 1998; Rom-
melspacher and Susilo 1985). In most cases, tetrahydroiso-
quinolines can be formed as condensation products of
biogenic amines (i.e., phenylethylamines and catechola-
mines) with aldehydes or a-keto acids by the so-called Pic-
tet–Spengler reaction (Rommelspacher and Susilo 1985;
Zarranz de Ysern and Ordonez 1981; Nagatsu 1997;
McNaught et al. 1998), although some of them may be also
synthesized enzymatically (Yamakawa and Ohta 1997,
1999; Naoi et al. 2004). The tetrahydroisoquinoline family
can be divided into compounds with catechol- and non-cat-
echol structure. TIQ is the simplest representative of the
group of non-catechol tetrahydroisoquinolines which occur
naturally in plants and in a variety of food products (Makino
et al. 1988; Niwa et al. 1989) as well as in the brain of
humans, primates, and rodents (Kohno et al. 1986; Makino
et al. 1988; Niwa et al. 1987; Ohta et al. 1987; Yamakawa
et al. 1999).
For the first time, tetrahydroisoquinolines attracted con-
siderable attention of neurochemists and pharmacologists
when Davis and Walsh (1970) demonstrated that the alcohol
metabolite acetaldehyde promoted in vitro conversion of
[14C]dopamine into [14C]tetrahydropapaveroline (THP).
Simultaneously, THP was identified in the urine of parkin-
sonian patients on L-DOPA (3,4-dihydroxyphenylalanine)
medication (Sourkes 1971; Sandler et al. 1973; Matsubara
et al. 1992) and in the urine and brain of rats treated with L-
DOPA (Turner et al. 1974). Almost at the same time,
salsolinol (6,7-dihydroxy-1-methyl-1,2,3,4-TIQ), an adduct
of dopamine and acetaldehyde, was identified in the urine of
non-pathologic human volunteers, occurring at high
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concentrations in the urine of intoxicated alcoholics (Collins
et al. 1979) and in brains of rats treated with ethanol (Collins
and Bigdeli 1975). Although TIQ has been proposed to be
one of the etiological factors of Parkinson’s disease (PD), its
implication in the pathogenesis is not clear, in contrast to
other tetrahydroisoquinolines with rather neurotoxic mech-
anism of action in the brain, e.g., salsolinol or 1-benzyl-
1,2,3,4-TIQ (1BnTIQ).
Early studies on tetrahydroisoquinolines revealed their
neuroleptic-like properties (Ginos and Doroski 1979) and
our more recent results suggest that TIQ and its derivatives
are antagonists of agonistic conformation of the dopamine
D2 receptor (Antkiewicz-Michaluk et al. 2007; Vetulani
et al. 2001, 2003a). This explains why TIQ and its congeners
effectively block dopaminergic stimulation without affect-
ing much the basal locomotor activity. Pharmacologi-
cally tetrahydroisoquinolines aroused also an interest as
potential NMDA (N-methyl-D-aspartate) receptor antagonists
(Ortwine et al. 1992). Some of them were described as effec-
tive antagonists of the phencyclidine (PCP) site (Rogawski
et al. 1989). However, most tetrahydroisoquinolines do not
substitute for PCP (Nicholson and Balster 2003).
Apart from TIQ, this group encompasses also, the
methyl derivative of TIQ, 1-methyl-1,2,3,4-TIQ (1MeTIQ),
is a neuroprotective compound. Among several endoge-
nous TIQs 1MeTIQ has a special position, as very early it
was described in the brain (Kohno et al. 1986; Makino
et al. 1990; Niwa et al. 1987; Ohta et al. 1987), and shortly
thereafter recognized as a potential antiparkinsonian
agent on the basis of reversal of bradykinesia induced
by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),
TIQ, or 1BnTIQ (Tasaki et al. 1991; Kotake et al. 1995).
1-MeTIQ was identified in normal rat brains in 1986
(Kohno et al. 1986), and subsequently found to be present
in foods rich in 2-phenylethylamine, from which it may
enter the brain (Makino et al. 1988). However, it is also
synthetized enzymatically in the brain from 2-phenethyl-
amine to pyruvate (Niwa et al. 1990; Tasaki et al. 1993;
Yamakawa and Ohta 1997). Having an asymmetric carbon
atom, 1MeTIQ may appear in the form of R- and S-ster-
eoisomers, and the product found in brain and in foods is a
racemate (Makino et al. 1990), although the stereoisomers
do not much differ in their biological actions (Abe et al.
2001; Wa˛sik et al. 2012). 1MeTIQ unlike several other
TIQs displays neuroprotective and antiaddictive properties
which will be particularly emphasized in this article
(Antkiewicz-Michaluk and Vetulani 2001; Antkiewicz-
Michaluk et al. 2003, 2004, 2006; Wa˛sik et al. 2007, 2010).
This article reviews some important aspects concerning
the chemistry, distribution, pharmacology, and mechanism
of action of TIQ and its methyl derivative, 1MeTIQ the
simplest representatives of the unsubstituted non-catechol
tetrahydroisoquinolines in the mammalian brain.
Synthesis of 1MeTIQ in the Brain
1MeTIQ was identified in normal rat brains by Kohno and
coworkers (Kohno et al. 1986), and subsequently found to
be present in foods rich in 2-phenylethylamine, which
readily penetrates into the brain across the blood–brain
barrier (Makino et al. 1988). 1MeTIQ may be also syn-
thesized enzymatically in the brain (Niwa et al. 1990). The
enzyme involved in that process called 1MeTIQase was
localized in the mitochondrial-synaptosomal fraction of rat
brain, isolated, and purified (Niwa et al. 1990; Tasaki et al.
1993). Its activity is spread throughout the brain, the
highest activity being observed in the dopaminergic areas
that are implicated in the etiology of PD [striatum and
substantia nigra (SN)] and in the cortex. During aging the
activity of 1MeTIQase falls (by approximately 40–50 %)
in the areas of its highest activity (Absi et al. 2002).
1MeTIQase may be important in the pathogenesis of PD.
The cerebral concentration of 1MeTIQ in normal rat brains
was recently determined as 3.5 ng/g tissue, exceeding
several times (three- to fivefold) the concentrations of other
simple tetrahydroisoquinolines (Inoue et al. 2008). Most of
the studies on 1MeTIQ were carried out on the brains of
rodents, but the results on monkeys demonstrate that the
regional distribution of 1MeTIQ, other simple tetrahydro-
isoquinolines, and 1MeTIQase activity are correlated
(Yamakawa et al. 1999).
It was also demonstrated that 1MeTIQ synthesis is
inhibited by agents that induce experimental parkinsonism
(Igarashi et al. 1999; Tasaki et al. 1991; Yamakawa and
Ohta 1999). Interestingly, the 1MeTIQ concentration in SN
declines in parkinsonian patients as well as in aged rats, by
as much as 50 % (Ayala et al. 1994). All those data indi-
cate that the change in 1MeTIQ content of brain may play
an important role in the pathogenesis of the toxin-induced
parkinsonism, and that the degeneration of dopaminergic
neurons may proceed as a result of the loss of neuropro-
tection afforded by 1MeTIQ. Thus, it seems that 1MeTIQ
is an endogenous substance that protects mainly dopamine
cells against free radical damage.
Neuroprotection
Free Radical Scavenging Properties Afforded by TIQ
and 1MeTIQ
To determine whether TIQ and 1MeTIQ may protect against
oxidative stress we investigated their capacity to inhibit
hydroxyl radical generation in vitro. Oxidative stress leads to
the production of reactive oxygen species (Harman 1981),
such as superoxide anion radical and hydroxyl radical
(OH)—chemical species known to damage cellular
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macromolecules (e.g., lipids, sugars, proteins), and this
damage can lead to equally damaging secondary products
(Sayre et al. 2008). Based on these data, oxidative stress was
long regarded as a universal mechanism of inducing cell
death (Dykens 1999). In the brain, the main source of toxic
OH formation and H2O2 generation is MAO, consequent to
monoamine deamination (for review see Singer and Ramsay
1995). Similarly, excessive intraneuronal dopamine catabo-
lism by MAO augments the formation of free radicals in the
brain. A direct study on the free radical scavenging capacity
of other tetrahydroisoquinolines was carried out in vitro in
rodent brain. Both TIQ and 1MeTIQ, in contrast to other
tetrahydroisoquinolines (e.g., 1BnTIQ and salsolinol), inhi-
bit MAOA and MAOB activities and possess other antioxi-
dant properties (Patsenka and Antkiewicz-Michaluk 2004),
as indicated by the effects of TIQ and 1MeTIQ to inhibit free
radical formation and abolish dopamine generation of OH
via the Fenton reaction (Antkiewicz-Michaluk et al. 2006).
Those results demonstrate that TIQ and 1MeTIQ, indepen-
dent of direct interaction with biological structures, possess
intrinsic antioxidant properties.
Neuroprotection in Relation to Dopaminergic
Mechanisms in In Vitro and Ex Vivo Studies
Interaction with presynaptic dopamine receptors was
investigated by studying 1MeTIQ-induced displacement of
dopamine receptor ligands from their binding sites. In gen-
eral, tetrahydroisoquinolines do not displace antagonistic
ligands bound to dopamine D2 receptors (Antkiewicz-
Michaluk et al. 2007; Vetulani et al. 2003a), the exception
being [11C]raclopride. Depression of binding of [11C]ra-
clopride may be interpreted as the sign of increased synaptic
dopamine concentrations, which competes with raclopride
at dopamine D2 receptor sites (Laruelle 2000). Tetrahydro-
isoquinolines were shown to displace [11C]raclopride, and
the (S)-enantiomers of TIQ and 1MeTIQ were most potent in
this respect. These findings suggest that tetrahydroisoquin-
oline analogs profoundly stimulate dopamine release,
resulting in the competitive inhibition of [11C]raclopride
binding to dopamine D2 receptors, but not loss of receptor
number (Ishiwata et al. 2001). The dopamine receptor ago-
nist [3H]apomorphine was another ligand displaced from
dopamine D2 receptors by tetrahydroisoquinolines (Ant-
kiewicz-Michaluk et al. 2007; Vetulani et al. 2003a). In
contrast to antagonists, an agonist radioligand binds pref-
erentially to the high-affinity state and is expected to have
greater sensitivity to dopamine, the endogenous agonist.
Thus, the experiments with [3H]apomorphine displacement
confirm that tetrahydroisoquinolines may release dopamine
from dopaminergic terminals. However, owing to their
MAO-inhibiting properties tetrahydroisoquinolines do not
cause neurodegeneration of dopaminergic neurons.
In biochemical studies, MPTP and pro-parkinsonian
b-carbolines potently inhibited the activity of 1MeTIQ-ase
(Yamakawa and Ohta 1999). It is well established by
behavioral, biochemical ex vivo but also in vivo microdi-
alysis studies, that both enantiomers (R)- and (S)- as well
as racemic (R,S)-1MeTIQ demonstrate neuroprotective
activity, as evidenced by their attenuation of the behavioral
and biochemical effects of dopaminergic neurodegenera-
tion induced by experimental neurotoxins such as: MPTP,
1BnTIQ, and rotenone (Antkiewicz-Michaluk et al. 2003,
2004, 2011; Kotake et al. 1995, 2005; Tasaki et al. 1991).
Several tetrahydroisoquinolines and their congeners,
including TIQ and 1MeTIQ, interfere with MAO activity,
indicating putative neuroprotection relating to the patho-
genesis of PD (Naoi and Maruyama 1993). Subsequently,
Thull et al. (1995) investigated 45 isoquinoline derivatives
and found most of them to be reversible inhibitors of MAOA
and MAOB, with preferential effects on the A form. Their
studies brought to the forefront the question of the physio-
logical significance of endogenous MAO inhibitors, and a
suggested role for endogenous tetrahydroisoquinolines in
the control of neurotransmitter function, and prevention of
neurotoxicity related to MAO activity in the brain.
The data from ex vivo neurochemical experiments have
shown stereospecificity of 1MeTIQ enantiomers, (R)- and
(S)- in respect of their effects on dopamine catabolism.
While both enantiomers increased the concentrations of
dopamine and its extraneuronal metabolite, 3-methoxytyr-
amine (3-MT) in rat striatum, they differently affected
dopamine catabolism. Thus, (R)-1MeTIQ increased both
the level of the final dopamine metabolite homovanillic acid
(HVA) (by about 70 %) and the rate of dopamine metabo-
lism (by 50 %), while (S)-1MeTIQ depressed the DOPAC
(3,4-dihydroxyphenylacetic acid) and HVA levels (by 60
and 40 %, respectively), and attenuated the rate of dopamine
metabolism (Antkiewicz-Michaluk et al. 2011). These data
suggest that the (S)-enantiomer may offer better and more
effective protection against neurotoxicity. It would be
important to mention that even after chronic administration
a high dose of 1MeTIQ never produced noxious effects on
dopamine neurons (Antkiewicz-Michaluk et al. 2001).
Showing structural resemblance to MPTP, the potent
neurotoxin capable of producing persistent parkinsonism in
humans (Langston et al. 1983) and in laboratory animals
(Jenner and Marsden 1986), initially all tetrahydroisoquin-
olines were assumed to be neurotoxic to dopamine neurons.
In fact, the early studies reported that they generally are
neurodegenerating agents (Suzuki et al. 1990), the most
neurotoxic being 1BnTIQ, and N-methyl derivatives, (R)-
1,2-dimethyl-5,6-dihydroxy-TIQ, (R)-N-methyl-salsolinol,
and TIQ (Nagatsu 1997). This finding contrasted with an
earlier report which found no neurotoxicity of tetrahydro-
isoquinolines on nigrostriatal dopamine neurons (Perry et al.
Neurotox Res (2014) 25:1–12 3
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1988). The most recent studies, in which the actions of
1MeTIQ and TIQ were directly compared, suggest that TIQ,
in fact, produces some damage to dopaminergic neurons, as
reflected by a mild but significant decrease in the striatal
dopamine concentration in rats chronically administered
TIQ in high doses (50–100 mg/kg). In contrast, 1MeTIQ has
never been shown to produce a decline in dopamine in brain,
although both of these tetrahydroisoquinolines similarly
affect dopamine catabolism (Antkiewicz-Michaluk et al.
2000a; 2001; Antkiewicz-Michaluk and Vetulani 2001).
Neuroprotection of 1MeTIQ Against Rotenone
Rotenone, a natural compound, is a classical, lipophilic
inhibitor of mitochondrial complex I (Gutman et al. 1970;
Horgan et al. 1968), and selectively toxic to dopaminergic
neurons (Marey-Semper et al. 1993). Rotenone, an envi-
ronmental toxin induces the formation of Lewy bodies,
which are the most characteristic histopathological feature of
Parkinson’s disease (Betarbet et al. 2000), and may be used to
produce a parkinsonian syndrome more realistic from MPP?
animal modeling of PD. A defect of mitochondrial function
due to complex I inhibition was postulated to be the cause of
rotenone-induced neurodegeneration (Jenner 2001; Greena-
myre et al. 2001). Rotenone also causes dopamine release, as
evidenced by microdialysis and neurochemical data (Santi-
ago et al. 1995; Thiffault et al. 2000), and this may also
contribute to the degeneration of dopaminergic neurons. In
our studies, rotenone administered in a single dose did not
produce evident behavioral or biochemical effect. In con-
trast, repeated administration of rotenone (12 mg/kg s.c.)
causing abnormalities in general behavior produced consid-
erable mortality and dramatic increases in dopamine
metabolism, which may be ascribed to an increase in the
oxidative pathway, and strongly depressed the concentration
of the extracellular dopamine metabolite, 3-MT. These
behavioral and biochemical changes were effectively coun-
teracted by administration of 1MeTIQ before each dose of
rotenone (Antkiewicz-Michaluk et al. 2003). In addition,
rotenone administered intracerebrally to the left medial
forebrain bundle (MFB) produced neurodegeneration of
dopamine neurons in extrapyramidal system (a considerable
decrease in dopamine and its metabolite levels) without
affecting the serotonin system (Antkiewicz-Michaluk et al.
2004). Those changes were observed 21 days after the
intracerebral injection of rotenone, they suggest a durable
neurotoxic effect. Peripheral administration of 1MeTIQ
(50 mg/kg i.p.) before, and then daily for 21 days, signifi-
cantly reduced the fall of striatal dopamine concentration
(Antkiewicz-Michaluk et al. 2004). The above data suggest
that 1MeTIQ is able to counteract the damaging action of
dopaminergic neurotoxin, rotenone and seems to be a
potential neuroprotective agent.
Neuroprotection of 1MeTIQ Against Glutamate-
Evoked Neurotoxicity
Recently, it was demonstrated that 1MeTIQ shares many
activities with TIQ, and found that the compounds similarly
inhibit free radical generation in an abiotic system, as well as
indices of neurotoxicity (caspase-3 activity and lactate
dehydrogenase release) induced by glutamate in mouse
embryonic primary cell cultures (Antkiewicz-Michaluk et al.
2006). However, in granular cell cultures obtained from
7-day-old rats, 1MeTIQ (in concentration-related manner)
prevented glutamate-induced cell death and 45Ca2? influx,
whereas TIQ did not. Such profile of action of 1MeTIQ
suggested specific effects of this compound on an excitatory
amino acids receptor. In addition, it was shown in an in vivo
microdialysis experiment that 1MeTIQ prevents kainate-
induced release of excitatory amino acids from the rat frontal
cortex (Antkiewicz-Michaluk et al. 2006).
Comparing the chemical structure of 1MeTIQ with other
known compounds containing TIQ skeleton and their
molecular mechanism of action, one can find similarities
between 1MeTIQ and these derivatives which are non-
competitive AMPA/kainate receptor antagonists that protect
animals in the maximal electroshock seizure, pentylenetet-
razole and audiogenic DBA/2 mouse seizure models (Ferreri
et al. 2004; Gitto et al. 2003). In fact, 1MeTIQ exerts anti-
convulsant effects, increasing the threshold for electrocon-
vulsions and potentiation of the antiseizure action of
carbamazepine and valproate against maximal electroshock
(Luszczki et al. 2006). In the light of all these experiments,
1MeTIQ offers a unique and complex mechanism of neu-
roprotection in which inhibitory effect on MAO connected
with free radicals scavenging properties, and antagonism to
the glutamatergic system seems to play a very important role.
Addiction
Addiction is a complex disease process of the brain which
results from recurring drug intoxication and is modulated by
genetic, experiential, and environmental factors. Drug
addiction is one of the most difficult medical and social
problems, as no effective pharmacotherapy has been avail-
able so far. Until recently, it was believed that addiction was
associated with neuroplasticity in the cortico-striatal brain
circuitry, which is important for adaptive behavior and
predominantly involved reward processes mediated by
limbic circuits, whereas results from recent neuroimaging
studies have implicated additional brain areas, especially the
frontal cortex (Goldstein and Volkov 2002). Drug addiction
is often defined by the pharmacological terms: tolerance,
sensitization, dependence, and withdrawal. Tolerance refers
to the phenomenon where repeated administration of a drug
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at the same dose causes a diminishing effect or a need for an
increasing drug dose to produce the same effect. Sensitiza-
tion refers to the opposite condition where repeated
administration of the same drug dose produces an escalating
effect. Interestingly, the same drug can simultaneously
evoke tolerance and sensitization to its numerous diverse
effects (e.g., in the case of morphine, tolerance to its anal-
gesic effect and sensitization to its locomotor effect).
Dependence is defined as a need for continual drug exposure
to avoid a withdrawal syndrome which is characterized by
physical or motivational disturbance when the drug is
withdrawn.
The neurobiological changes that accompany drug
addiction have not been understood so far; however, drugs
of abuse are unique in terms of their reinforcing properties.
Dopaminergic mechanisms are a traditional target in the
field of addiction, as the acute rewarding effects of
addictive drugs are mediated by enhancing dopamine
transmission; moreover, dopamine release reinforces
reward learning (Berridge and Robinson 1998; Kelley
2004a, b). A question arises about the neurobiological
substrate of reward. The nucleus accumbens (NAc) as a
ventral striatum is considered to be a crucial point of
integration of information by receiving emotional and
cognitive inputs, and by projecting to motor output regions
(Mogenson et al. 1980; Kelley 2004a). The NAc, along
with the hippocampus, frontal cortex (FCx), and basolat-
eral amygdala, receives dopamine input from the ventral
tegmental area (VTA); furthermore, as it has been shown
by many others, the majority of dopamine neurons that
innervate the forebrain are located in the midbrain, spe-
cifically in the VTA and SN (Fallon and Loughlin 1995;
Pitkanen 2000). The SNc innervates the dorsal striatum
(caudate–putamen), whereas the VTA provides an input to
the rest of the forebrain, including the ventral striatum
(NAc), FCx, amygdala, and hippocampus. Early theories
on drugs of abuse and natural rewards suggested that
activation of dopamine neurons in VTA, and the release of
dopamine in target structures signaled reward, especially in
the NAc (Di Chiara 2002; Ungless 2004). However, aver-
sive stimuli also increase dopamine release in a variety of
brain structures, which indicates a role of dopamine beyond
reward (Inglis and Moghaddam 1999). It is noteworthy that
some evidence points to differential dopamine responses to
aversive versus rewarding stimuli (Schultz 2002, 2010).
Some recent studies have also shown that the glutamate
system and its release is an important factor in drug
addiction, and that imbalance in glutamate homeostasis
engenders changes in neuroplasticity, which impair com-
munication between the prefrontal cortex and the NAc
(Kalivas 1995; Ma et al. 2006; Nagy 2004; Popik et al.
1998). In a clinical setting, neuroimaging studies have
shown that cue or drug exposure increased the activity of
FCx and NAc, as well as self-reported drug craving in
cocaine addicts (Goldstein and Volkov 2002). In animal
models, a challenge of cocaine or heroin increases the
synaptic release of glutamate in cocaine- or heroin-with-
drawn rats as a result of the activation of corticostriatal
pathways; and on the other hand, inactivation of the cor-
ticostriatal pathway has been shown to be effective in
inhibiting cocaine- or heroin-induced drug seeking behav-
ior (Kalivas et al. 2005).
Cocaine Addiction: The Effect of 1MeTIQ
Regardless of the mechanism of action of drugs of abuse,
the essential role of the mesolimbic dopaminergic system
in addiction has been well established (Goldstein and
Volkov 2002; Grimm et al. 2003; Moore et al. 1998a, b); to
this end, several antidopaminergic drugs were tested as
potential anti-abuse agents (Berger et al. 1996; Smelson
et al. 2004). Although neuroleptics were previously found
not to be useful in this respect, partial agonists of the
dopamine D2 and D3 receptor aroused some hopes
(Campiani et al. 2003; Le Foll et al. 2005; Mach et al.
2004). Furthermore, a dopamine reuptake inhibitor could
be expected to partially substitute for cocaine and other
drugs of abuse, hence self-administration would be
diminished and craving minimized (Ritz et al. 1987; Wil-
cox et al. 2000; Carroll et al. 2004). This type of substi-
tution pharmacotherapy has been found to be highly
effective in the treatment of nicotine and heroin addiction
(methadone). Hence, studies of partial agonists with an
antidopaminergic profile of action different from that of
classic neuroleptics seem justified. In the light of the above
data, 1MeTIQ is an interesting candidate for future clinical
studies.
A vast body of evidence indicates that, apart from the
dopaminergic system, also the glutaminergic system is
involved in the addiction to drugs of abuse. Hence, of
special interest are the observations that 1MeTIQ antago-
nizes the kainate-induced release of glutamate and aspar-
tate in rat FCx and shows neuroprotection against the
excitotoxicity produced by glutamate in cultured cells
(Antkiewicz-Michaluk et al. 2006). In addition, 1MeTIQ
antagonizes the MK-801-produced behavioral and neuro-
chemical effects (Pietraszek et al. 2009) and shares toler-
ance to excitotoxicity in rat with some well-established
uncompetitive NMDA receptor antagonists (Kuszczyk
et al. 2010). The latest results reveal a new mechanism of
the 1MeTIQ-evoked neuroprotection based on the induc-
tion of neuronal tolerance to excitotoxicity.
It is well known that acute administration of the drugs of
abuse: cocaine, amphetamine (psychostimulants), and
opiates increases the locomotor activity of animals. Repe-
ated administration of the drug of abuse induces
Neurotox Res (2014) 25:1–12 5
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neurobiological changes, such that after 10 days of with-
drawal, acute administration of the drug produces an even
greater increase in locomotor activity, a process called
sensitization. Both behavioral sensitization, self-adminis-
tration, and drug-reinstatement of seeking behavior are the
major models of drug addiction (Pierce and Kalivas 1997).
The compounds which antagonize locomotor sensitization
and self-administration in animals may demonstrate anti-
addictive properties in a clinic (Narayanan et al. 1996).
Exogenously applied 1MeTIQ significantly antagonized
cocaine-induced locomotor sensitization, cocaine self-
administration, and cocaine-induced reinstatement of seek-
ing behavior (Filip et al. 2007; Wa˛sik et al. 2010). The
phenomenon is of interest, as it might be caused by the same
mechanisms as those responsible for psychoses or craving
for drugs of abuse in humans abusing cocaine or other psy-
chostimulants (Robinson and Berridge 1993; Segal et al.
1981). Both clinical and preclinical studies indicate that the
behavioral response to cocaine, including the discriminative
stimulus and rewarding effects as well as reinstatement of
cocaine seeking behavior, depends on the drug’s ability to
block the dopamine transporter (Di Chiara 1995; Heidbreder
and Hagan 2005). As 1MeTIQ produced parallel decreases in
cocaine self-administration and cocaine-induced relapse, the
compound may suppress the motivation for drug seeking by
decreasing the reinforcing effects of cocaine, and generally
by attenuation of the reinforcing effect of drugs of abuse. In
fact, activation of both the dopaminergic and the glutamin-
ergic systems has significance in altering the maintenance of
cocaine self-administration (Cornish et al. 1999; Pulvirenti
et al. 1992), and drug-priming-induced reinstatement of
cocaine seeking (Ito et al. 2002; Kalivas and McFarland
2003).
1MeTIQ’s inhibitory mechanism on cocaine maintained
responding and relapse may include complex interactions
with both dopaminergic and/or glutaminergic transmission.
Neurochemical Changes Produced by 1MeTIQ
in Cocaine-Dependent Rats
Cocaine, a potent inhibitor of monoamine transporters,
belongs to the most powerful addictive substances in humans
and its abuse has a high risk of relapse (Gawin 1991). Studies
on the involvement of biogenic amines in cocaine addiction
have shown a contribution of dopamine and serotonin to the
maintenance of cocaine self-administration, extinction, and
reinstatement of drug-seeking behavior. Dopamine was the
amine investigated the most extensively, possibly because of
its assumed role as the main neurotransmitter of reward (Di
Chiara et al. 2004). It was demonstrated by several authors
during cocaine self-administration, that extracellular con-
centrations of dopamine and serotonin in the striatum
increase (Di Ciano et al. 1995; Gratton and Wise 1994;
Wa˛sik et al. 2010), but the rate of monoamines metabolism
and the concentrations their metabolites in brain structures
decrease (Antkiewicz-Michaluk et al. 2006). The functional
significance of the observed depression of the level of
monoamine metabolites requires explanation. The determi-
nation of changes in metabolism rate yields information
about efficiency of the neurotransmitter system. Depending
on the state of receptor and the rate of synthesis of a neuro-
transmitter, the changes in metabolite levels in the same
direction may have different consequences. Activation of a
receptor (e.g., dopamine receptor) during stabilized self-
administration of cocaine would result in a feedback inhi-
bition of neurotransmitter release by activation of autore-
ceptors, and the depression of neurotransmitter metabolites
without significant changes in neurotransmitter concentra-
tion in the neuron. This is reflected by a decrease in the
neurotransmitter metabolism index. As the stimulation is
indirect, through inhibition of neurotransmitter reuptake, the
interaction between the neurotransmitter and receptor is
enhanced rather than depressed. On the contrary, during
cocaine withdrawal, dopamine and noradrenaline concen-
trations as well as concentration of their metabolites were
diminished, suggesting cocaine-induced impairment in the
function of catecholamine neurons, and a consequent
decrease in the synthesis and release of neurotransmitters
(Parsons et al. 1995; Weiss et al. 1992; Antkiewicz-Mich-
aluk et al. 2006).
While catecholamines seem to be involved in cocaine
addiction, the role of serotonin seems to be limited. Spe-
cific serotonin agonists do not seem to have significant
reinforcing efficacy (Locke et al. 1996). Clinical findings
also indicate inefficiency of serotonergic manipulation in
combating cocaine dependence (Lima et al. 2003).
Although, serotonin metabolism is inhibited in the presence
of cocaine, in contrast to alterations in catecholaminergic
system, the change was transient.
Basically, a chronic cocaine self-administration simi-
larly to passive administration suppresses the metabo-
lism—both synthesis and release of monoamines in several
brain structures (Karoum et al. 1990; Trulson and Ulissey
1987; Antkiewicz-Michaluk et al. 2006). The changes in
catecholamine metabolism persist for a considerable period
after cessation of cocaine self-administration, suggesting a
long-lasting functional impairment of dopamine and nor-
adrenaline systems. In contrast, changes in the serotonergic
system are transient, showing the lack of involvement of
serotonin in long-term consequences of cocaine exposure
(Antkiewicz-Michaluk et al. 2006).
It is suggested that 1MeTIQ is a potential anti-abuse agent,
as the drugs which reduce cocaine seeking behavior also
reduce cocaine craving (Fuchs et al. 1998; Baker et al. 2001).
The possible anti-abuse properties of 1MeTIQ are particularly
interesting, as the compounds of this group are proposed to act
6 Neurotox Res (2014) 25:1–12
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as regulators of brain homeostasis (Antkiewicz-Michaluk
et al. 2000a, b; Vetulani 2001). The question arises whether
1MeTIQ can reach the brain in concentrations producing
pharmacological effects? In contrast to catechol TIQs (e.g.,
salsolinol), non-catechol TIQs such as TIQ and 1MeTIQ
penetrate to the brain easily and induce a variety of central
effects. No direct measurements of 1MeTIQ concentration in
the brain after peripheral administration of the compound
have been carried out, but its close congener, TIQ after
administration of 40 mg/kg reached the concentration of
250 nmole/g in rat (Lorenc-Koci et al. 2004).
In cocaine-dependent rats receiving a priming dose of
cocaine in the presence of previously administered 1MeTIQ,
the concentration of dopamine in limbic structures was sig-
nificantly higher than in rats receiving cocaine alone. It
might be assumed that the blockade of reinstatement by
1MeTIQ is related to this effect (Antkiewicz-Michaluk et al.
2007). There is the long established view that depression of
dopaminergic activity in the limbic structures may be
responsible for craving (Rossetti et al. 1992; Little et al.
1996). Because 1MeTIQ elevates the concentration of
dopamine preferentially in limbic structures (NAc) in
cocaine-dependent rats, and at the same time inhibits dopa-
mine metabolism in structures containing cell bodies (SN,
VTA), 1MeTIQ may be responsible for its inhibition of
reinstatement (Antkiewicz-Michaluk et al. 2007).
Another neurochemical action of 1MeTIQ, possibly
related to its anticraving effect, is activation of the norad-
renergic system in the brain. This effect may be related to
the antagonistic action of 1MeTIQ on alpha-2-adrenocep-
tors. Such an activity was described previously for other,
closely related TIQs (Michaluk et al. 2002; Vetulani et al.
2003a, b). The ability of 1MeTIQ to increase the level of
the main metabolite of noradrenaline in CNS, 3-methoxy-
4-hydroxyphenylglycol (MHPG), as well as its extraneu-
ronal metabolite normetanephrine (NM), reflects the
antagonistic effect of 1MeTIQ on the alpha-2-adrenoceptor
(Antkiewicz-Michaluk, unpublished data). Inhibition of
alpha-2-adrenoceptors would result in an increase in nor-
adrenaline release from the nerve endings, and conse-
quently activation of the noradrenergic system.
In the light of the recent experimental data it looks as
though serotonin plays a less important role in the phe-
nomenon of cocaine reinstatement. It was shown that
cocaine depresses serotonin metabolism only transiently,
and that the changes do not persist throughout the with-
drawal period, in contrast to dopamine and noradrenaline
systems (Antkiewicz-Michaluk et al. 2007).
Morphine Addiction and the Effect of 1MeTIQ
Morphine acts through activation of opioid l-receptors and
produces the antinociceptive effect called analgesia. It is well
known that activation of opioid l-receptors is closely related
with inhibition of calcium uptake and this process is respon-
sible for opioid-induced analgesia (Kamikubo et al. 1983;
Chapman and Way 1982). 1MeTIQ administered alone was
shown to have a slight antinociceptive effect in the ‘‘hot-plate’’
test in rats, but co-administration of morphine strongly
potentiated its analgesia (Wa˛sik et al. 2007; Vetulani et al.
2003a, b). Moreover, 1MeTIQ applied before each morphine
injection completely inhibited the development of morphine
tolerance, and prevented naloxone-induced precipitation of the
abstinence syndrome (head-twiches and body weight loss) in
morphine-dependent rats (Wa˛sik et al. 2007). A question arises
as to the mechanism responsible for 1MeTIQ-induced poten-
tiation of morphine-analgesia, prevention of morphine-pro-
duced tolerance, and abstinence syndrome. Some have
postulated that the activity of MAO, the enzyme crucial for
monoamine and special dopamine catabolism, and the pro-
duction of free radicals, play an important role in opiate
analgesia, tolerance, and dependence (Garzon et al. 1979;
Grassing and He 2005). In fact, the irreversible MAOB
inhibitor deprenyl and other antioxidants such as vitamin C
produced an increase in morphine antinociception and pre-
vention of the development of morphine tolerance and physical
dependence in rodents (Sa´nchez-Bla´zquez et al. 2000; Khanna
and Sharma 1983). 1MeTIQ, a neuroprotective substance,
inhibits MAO and possesses free radical scavenging properties
(Antkiewicz-Michaluk et al. 2006). This mechanism would be
partially responsible for its antinociception and antiaddictive
effects. In addition, it has been shown that 1MeTIQ is also
effective in prevention of morphine-induced place preference
and alcohol intake (Antkiewicz-Michaluk et al. 2005).
Moreover, others have shown that morphine did not effec-
tively trigger the processes leading to development of tolerance
and dependence when administered during Ca2? channel
blockade. Blockade of the voltage-dependent L-type Ca2?
channels effectively facilitates the analgesic action of mor-
phine and prevents the behavioral and neurochemical signs of
naloxone-precipitated abstinence syndrome (Contreras et al.
1988; Del Pozo et al. 1987; Michaluk et al. 1998). NMDA
glutamate receptor activation and associated Ca2? influx may
also be involved in the induction of morphine sensitization
(Vanderschuren and Kalivas 2000). It should be taken into
account that 1MeTIQ prevented glutamate-induced cell death
and 45Ca2? influx in granular cell cultures (Antkiewicz-
Michaluk et al. 2006). Thus, 1MeTIQ besides the inhibitory
influence on the activity of MAO and free radical scavenging
properties possesses mild activity at NMDA receptors.
Conclusions
The experimental data assembled in this review allow for a
more precise characterization of the activity of the
Neurotox Res (2014) 25:1–12 7
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exogenous 1MeTIQ in the mammalian brain, especially in
the nigrostriatal dopaminergic system. On the basis of these
studies, the following conclusions may be drawn:
• exogenous 1MeTIQ has high affinity for brain tissue
• 1MeTIQ is a partial dopamine agonist
• 1MeTIQ reversibly inhibits MAOA and MAOB:
in vitro and in vivo studies
• 1MeTIQ is a scavenger of free radicals
• 1MeTIQ expresses neuroprotective properties
• 1MeTIQ demonstrates antiaddictive potency
This ability of 1MeTIQ may be of clinical importance
and raises hope for its application in neurodegenerative
diseases (e.g., Parkinson’s disease) and addiction evoked
by drugs of abuse.
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